Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

The team from Cancer Research UK's Manchester Institute says it has created a new in vitro model of lung squamous cell ...

Design We developed a mouse model that closely resembles EoE by utilising oxazolone haptenation in mice with transgenic overexpression of an eosinophil poietic and survival factor (interleukin (IL)-5) ...

In contrast, physiological cell shedding allows the renewal of the epithelial monolayer without compromising the barrier function. Here, we investigated the role of live cell extrusion in epithelial ...

How do dermatologists diagnose squamous cell skin cancer? When you see a board-certified dermatologist for a spot that might be skin cancer, your dermatologist will examine your skin carefully. If ...

There are two main types of lung cancer: non-small cell lung cancer and small cell lung cancer. People with non-small cell lung cancer tend to have a better prognosis than people with small cell lung ...

Major Finding: A cancer-associated fibroblast (CAF)–epithelial cell niche shields squamous cell carcinomas (SCC) from antitumor immune responses. Concept: Epithelial JAG1–NOTCH1 signaling promotes the ...

Squamous cell cancer (SCC) is a type of skin cancer. To determine the severity of SCC, doctors use a staging system. There are five stages in total, ranging from 0 to 4. SCC stages describe the ...

Corneal diseases can cause severe visual impairment and even blindness, which have been linked to the interruption of corneal epithelial homeostasis. However, the underlying molecular mechanisms are ...

According to the American Cancer Society, those with stage 4 non-small cell lung cancer (NSCLC) diagnosed between 2012 and 2018 had a five-year relative survival rate of 9%. However, that doesn't tell ...